Sitemap

EU Commission Concludes Exploratory Talks With Valneva To Secure A New Potential Vaccine

More...

In Europe, Optimism And Reluctance As COVID Vaccines Arrive

There appears to be nearly as much...

Connectivity For A Higher Quality Of Life

“Where there’s a will, there’s a way.” Perhaps...

Why Are So Many Serbian Doctors Dying Of COVID-19?

Serbia’s total death toll from coronavirus is...

Chairperson-In-Office Ann Linde Presents Sweden’s 2021 Priorities To Permanent Council

Over the coming year, the Swedish Chairpersonship...

News

Connectivity For A Higher Quality Of Life

“Where there’s a will, there’s a way.” Perhaps this was the motto of a group of friends from the Greek...

Chairperson-In-Office Ann Linde Presents Sweden’s 2021 Priorities To Permanent Council

Over the coming year, the Swedish Chairpersonship will do its part to ensure that the OSCE can make a...

Tokyo’s Covid Outbreak Adds To Doubts Over Hosting Olympic Games

A dramatic rise in coronavirus cases in Tokyo has reignited speculation about the Olympic Games, which are due to open...

Environmental Protection – EU-Serbia Cooperation

The year behind us was certainly challenging in terms of health protection. Healthy environment was an essential aspect of...

EU Commission Concludes Exploratory Talks With Valneva To Secure A New Potential Vaccine

European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against...

European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19.

The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses.

Today’s finalisation of exploratory talks with Valneva come in addition to an already secured broad portfolio of vaccines to be produced in Europe, including the contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, and Moderna and exploratory talks concluded with Novavax. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective, as is already the case for BioNTech/Pfizer and Moderna, recently authorised in the EU. Member States are able to donate vaccines to lower and middle-income countries or to re-direct it to other European countries.

President of the European Commission, Ursula von der Leyen, said: “The continuing COVID-19 pandemic in Europe and around the globe makes it more important than ever that all Member States have access to the broadest possible portfolio of vaccines to help protect people in Europe and beyond. Today’s step toward reaching an agreement with Valneva further complements the EU’s vaccines portfolio and demonstrates the Commission’s commitment to find a lasting solution to the pandemic.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: With this eighth vaccine, we are adding to our already broad and diversified range of vaccines in our portfolio. By doing this, we can maximise our chances of making sure that all citizens can have access to safe and effective of vaccinations by the end of 2021. All Member States have now started their vaccination campaigns and will start receiving an increasing number of doses in order to cover all their needs during this year.”

Valneva is a European biotechnology company developing an inactivated virus vaccine. This is a traditional vaccine technology, used for 60-70 years, with established methods and a high level of safety. Most of the influenza vaccines and many childhood vaccines use this technology. This is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

The Commission, with the support of EU Member States, has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the company’s experience in vaccine development and its production capacity to supply all EU Member States.

Related Articles

In Europe, Optimism And Reluctance As COVID Vaccines Arrive

There appears to be nearly as much skepticism of the vaccines that could eventually put an end to the coronavirus pandemic as there is...

Connectivity For A Higher Quality Of Life

“Where there’s a will, there’s a way.” Perhaps this was the motto of a group of friends from the Greek village of Sarantaporo who decided to create...

Why Are So Many Serbian Doctors Dying Of COVID-19?

Serbia’s total death toll from coronavirus is relatively low, around 3,600, but its rate of fatalities in the medical profession is far higher than...

Chairperson-In-Office Ann Linde Presents Sweden’s 2021 Priorities To Permanent Council

Over the coming year, the Swedish Chairpersonship will do its part to ensure that the OSCE can make a real difference on the ground...

Tokyo’s Covid Outbreak Adds To Doubts Over Hosting Olympic Games

A dramatic rise in coronavirus cases in Tokyo has reignited speculation about the Olympic Games, which are due to open in the city in just...

Environmental Protection – EU-Serbia Cooperation

The year behind us was certainly challenging in terms of health protection. Healthy environment was an essential aspect of these efforts, and in 2020,...

Preconditions For Beginning Of Mass Vaccination Provided

Prime Minister Ana Brnabic pointed out today that there will be enough vaccines available for all citizens who want to be vaccinated against coronavirus. During...

Strong Support In Favour Of EU Accession Among Serbian Citizens

Better economic standards, higher salaries and pensions, future job opportunities, visa-free travelling benefits are some of the first associations with the EU according to the latest...